Clinipace Acquisition Pan-Asia CRO, Choice Pharma

Published on: 

Applied Clinical Trials

Choice Pharma provides Clinipace a significant Pan-Asia footprint

Clinipace Worldwide announced its merger with Choice Pharma. The merger expands Clinipace's global reach to include new offices in Taiwan, China, Hong Kong, South Korea, Vietnam, Singapore, and Malaysia.

The combined company now has 640 staff in 30 countries, and experience managing over 1500+ clinical trials, and over 300 regulatory and strategic development engagements

There are no layoffs or office closings planned; and the new combined organization will continue to hire throughout the year. Terms of the transaction will not be disclosed.

This is the 5th acquisition by Clinipace in recent years.


Read the full release here.